Monte Rosa Therapeutics
GLUE
71 hedge funds and large institutions have $201M invested in Monte Rosa Therapeutics in 2023 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 31 increasing their positions, 17 reducing their positions, and 4 closing their positions.
134% more call options, than puts
Call options by funds: $1.36M | Put options by funds: $580K
82% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 17
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
4.65% more ownership
Funds ownership: 80.49% → 85.14% (+4.6%)
4% more funds holding
Funds holding: 68 → 71 (+3)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
26% less capital invested
Capital invested by funds: $272M → $201M (-$70.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$12.2M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
+$5.11M |
| 3 |
TD Asset Management
Toronto,
Ontario, Canada
|
+$493K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$461K |
| 5 |
Two Sigma Investments
New York
|
+$430K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.48M |
| 2 |
BlackRock
New York
|
-$1.07M |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
-$323K |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$213K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$167K |
GLUE Hedge Fund Activity: Q3 2023 in Review
71 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Monte Rosa Therapeutics (GLUE) for Q3 2023, worth a combined $201M — down 26% from $272M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new GLUE positions and 4 closed out — a net gain of 3 holders — while 31 added to existing stakes and 17 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $12.2M. The largest seller was Fidelity Investments, cutting an estimated $3.48M.
- 71 institutional investors held Monte Rosa Therapeutics (GLUE) as of Q3 2023, up from 68 in Q2 2023.
- Funds reported $201M of Monte Rosa Therapeutics stock for Q3 2023, down 26% quarter-over-quarter.
- 7 funds opened new Monte Rosa Therapeutics positions in Q3 2023 and 4 closed out, a net change of +3 holders.
- The largest Monte Rosa Therapeutics buyer in Q3 2023 was Baker Bros. Advisors, an estimated $12.2M added.
- The largest Monte Rosa Therapeutics seller in Q3 2023 was Fidelity Investments, an estimated $3.48M sold.
Based on aggregated 13F filings for Q3 2023.